All questions
Clinical trials: Paxlovid (nirmatrelvir; ritonavir) in COVID-19 10 questions · 3 sources
Clinical trials questions that apply to every indication of Paxlovid are on Paxlovid (nirmatrelvir; ritonavir), all indications: Clinical trials .
Study results How much did Paxlovid lower viral load vs placebo by Day 5 (EPIC-HR, EPIC-SR)? Note: The EPIC-SR value is for all EPIC-SR participants, who included unvaccinated adults without risk factors, a population for which Paxlovid is not indicated.
How well does Paxlovid prevent COVID-19 hospitalization or death vs placebo (EPIC-HR)? Note: Table 9 columns are PAXLOVID (N=977) followed by placebo (N=989).
Did fewer people die on Paxlovid than placebo in EPIC-HR? Note: The first value is PAXLOVID (N=977) and the second placebo (N=989), from Table 9 of the Prescribing Information (EPIC-HR, mITT1 analysis set).
How effective was Paxlovid when started within 3 days of symptoms (EPIC-HR)? Note: Results are COVID-19-related hospitalization or death from any cause through Day 28 compared with placebo.
What were the results of the Paxlovid EPIC-SR trial? “EPIC-SR (NCT05011513) was a Phase 2/3, randomized, double-blind, placebo-controlled trial in non-hospitalized symptomatic adult subjects with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Eligible subjects were 18 years of age or older with COVID-19 symptom onset of ≤5 days who were at standard risk for progression to severe disease. The trial included previously unvaccinated subjects with no risk factors for progression to severe disease or subjects fully vaccinated against COVID-19 (i.e., completed a primary vaccination series) with at least 1 of the risk factors for progression to severe disease as defined in EPIC-HR. Through the December 19, 2021, data cutoff, a total of 1,075 subjects were randomized (1:1) to receive PAXLOVID or placebo orally every 12 hours for 5 days; of these, 59% were fully vaccinated high-risk subjects.
The primary endpoint in this trial, the difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 among PAXLOVID versus placebo recipients, was not met.
In an exploratory analysis of the subgroup of fully vaccinated subjects with at least 1 risk factor for progression to severe disease, a non-statistically significant numerical reduction relative to placebo for the secondary endpoint of COVID-19 related hospitalization or death from any cause through Day 28 was observed.” (opens the source at this quote in a new tab) Copy Flag
Note: EPIC-SR also enrolled unvaccinated adults without risk factors, a population for which Paxlovid is not indicated. The hospitalization or death result in vaccinated high-risk participants was an exploratory analysis.
Clinical trials How was the Paxlovid EPIC-HR trial designed? “EPIC-HR (NCT04960202) was a Phase 2/3, randomized, double-blind, placebo-controlled trial in non-hospitalized symptomatic adult subjects with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Eligible subjects were 18 years of age and older with at least 1 of the following risk factors for progression to severe disease: diabetes, overweight (BMI >25), chronic lung disease (including asthma), chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medically-related technological dependence, or were 60 years of age and older regardless of comorbidities. Subjects with COVID-19 symptom onset of ≤5 days were included in the study. Subjects were randomized (1:1) to receive PAXLOVID (nirmatrelvir/ritonavir 300 mg/100 mg) or placebo orally every 12 hours for 5 days. The trial excluded individuals with a history of prior COVID-19 infection or vaccination and excluded individuals taking any medications with clinically significant drug interactions with PAXLOVID. The primary efficacy endpoint was the proportion of subjects with COVID-19 related hospitalization or death from any cause through Day 28. The analysis was conducted in the modified intent-to-treat (mITT) analysis set [all treated subjects with onset of symptoms ≤3 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic monoclonal antibody (mAb) treatment], the mITT1 analysis set (all treated subjects with onset of symptoms ≤5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment), and the mITT2 analysis set (all treated subjects with onset of symptoms ≤5 days).” (opens the source at this quote in a new tab) Copy Flag
What were the most common risk factors in Paxlovid EPIC-HR patients? Subgroup results How effective was Paxlovid by age group in EPIC-HR? Note: Results are COVID-19-related hospitalization or death from any cause through Day 28 compared with placebo in the mITT1 analysis set.
Did Paxlovid work in EPIC-HR patients with prior SARS-CoV-2 antibodies? Interpreting study results What are the limitations of the Paxlovid EPIC-HR trial?